- 1 Title: Can long-term COVID-19 vaccination be improved by serological surveillance?: a
- 2 modeling study for Mozambique
- 3
- 4 Authors: Carol Y Liu<sup>\*1</sup>, Kayoko Shioda<sup>2</sup>, Alicia NM Kraay<sup>3,4</sup>, Sergio Massora<sup>5</sup>, Áuria de Jesus<sup>5</sup>,
- 5 Arsénia Massinga<sup>5</sup>, Celso Monjane<sup>6</sup>, Saad B Omer<sup>7</sup>, Samuel M Jenness<sup>1</sup>, Kristin Nelson<sup>1</sup>,
- 6 Stefan Flasche<sup>8</sup>, Inacio Mandomando<sup>5</sup>, Benjamin A Lopman<sup>1</sup>
- 7 8
- 9 <sup>1</sup> Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA
- <sup>2</sup> Department of Global Health, Boston University School of Public Health, Boston, MA, USA
- <sup>3</sup> Department of Kinesiology and Community Health, College of Applied Health Sciences, University of
- 12 Illinois Urbana-Champaign, IL, USA
- 13 <sup>4</sup>Institute for Genomic Biology, Unviersity of Illinois Urbana-Champaign, IL, USA
- <sup>5</sup> Centro de Investigação em Saúde de Manhiça (CISM), Maputo CP1929,
- 15 <sup>6</sup> Mozambique Instituto Nacional de Saúde, Maputo, Mozambique
- 16 <sup>7</sup>School of Medicine, Yale University
- <sup>17</sup> <sup>8</sup>Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical
- 18 Medicine
- 19
- 20 Main text word count: 4,937 (Allowed: 5000)

## 21 Abstract (Word count: 199)

22 Seroprevalence provides an estimate of the population-level susceptibility to infection. In this 23 study, we used a transmission model to examine the potential of using serological surveillance to inform the timing of COVID-19 boosters in Mozambigue. We simulated using population-level 24 25 seroprevalence thresholds as an estimate of the risk of outbreaks to trigger the timing of re-26 vaccination campaigns among older adults. We compare this approach to a strategy of revaccination at fixed time intervals. Vaccinating older adults each time the seroprevalence 27 28 among older adults falls below 50% and 80% resulted in medians of 20% and 71% reduction in deaths, respectively, and number-needed-to-vaccinate to avert one death (NNT) of 1,499 (2.5<sup>th</sup>-29 30 97.5<sup>th</sup> centile:1,252-1,905) and 3,151 (2,943-3,429), respectively. In comparison, biennial and annual re-vaccination of older adults resulted in medians of 35% and 52% deaths averted. 31 32 respectively, and NNTs of 1,443 (1,223-1,733) and 1,941 (1,805-2,112), respectively. We conducted sensitivity analysis over a range of antibody waning rates and epidemic scenarios 33 and found that re-vaccination trigger thresholds of 50-60% seroprevalence are most likely to be 34 efficient compared to fixed-time strategies. However, given marginal gains in efficiency even in 35 the best-case scenarios, our results favor the use of simpler fixed-time strategies for long-term 36 control of SARS-CoV-2. 37

#### 39 Background

40 Vaccines are a pivotal tool for SARS-CoV-2 control, eliciting strong protection against severe

41 disease and death for vaccinated individuals<sup>1–3</sup>. Since the beginning of global vaccine rollout in

42 December 2020, COVID-19 vaccines averted an estimated 19.8 million deaths in 185 countries

43 and territories<sup>4</sup>. Vaccination programs enabled safer relaxation of non-pharmaceutical

44 interventions (e.g., social distancing), which facilitated a transition away from the most severe

45 phase of the pandemic<sup>5,6</sup>.

46 Despite early successes of SARS-CoV-2 vaccines, evidence of waning immunity and the

47 emergence of novel immune-escaping variants raised concern over the longevity of vaccine-

48 induced protection. Since the rise of the highly infectious Omicron variant, effectiveness of the

49 primary series of mRNA vaccines against hospitalizations reduced by almost half compared to

50 protection estimated from the first clinical trials<sup>7</sup>. Booster doses partially restored short-term

51 protection, prompting their strong recommendation for those most at risk of developing severe

52 outcomes<sup>8,9</sup>. Repeated booster campaigns aimed at restoring protection against severe

53 disease among high risk groups remains an important tool in the medium- to long-term<sup>10,11</sup>.

54 Effective deployment of vaccines maximizes their public health impact. While population

55 immunity against SARS-CoV-2 was still low, targeted vaccine prioritization rapidly increased

56 protection for vulnerable portions of the population, beginning with those at the highest risk for

57 severe outcomes and deaths. Long-term control of COVID-19 requires the consideration of

refined and information-driven strategies that optimizes vaccine efficiency, ideally preventing the

59 greatest number of severe health outcomes with the fewest resources. Identifying critical time

60 periods and targeting population groups most susceptible to impending waves can minimize

61 resource needs while maximizing public health impact.

62 Serology, a marker for prior exposure determined by the presence of antibodies against SARS-

63 CoV-2 in blood serum, also provides information on the degree of susceptibility to infection or

64 disease in individuals. Seroprevalence of randomly sampled individuals provides an estimation

of population-level susceptibility, and has previously influenced vaccination strategy. When

serological studies from England<sup>12,13</sup> identified waning SARS-CoV-2 seroprevalence among the

oldest age groups, an additional booster targeting this group was recommended.

68 Seroprevalence estimates are further leveraged to guide vaccination strategies for endemic

69 infections. In the case of measles, a fully-immunizing infection with a high reproduction number,

50 seroprevalence is used to identify locations and age groups with inadequate immunity for

targeted vaccination campaigns. By providing snapshots of the landscape of population-level

immunity before surges in hospitalizations and deaths, seroprevalence estimates enabled

73 preemptive vaccination of the most susceptible population groups<sup>14</sup>.

74 The use of serological surveillance, specifically measuring seroprevalence, to monitor changing immunity for SARS-CoV-2 at the population level and to trigger vaccination campaigns emerged 75 as a potential long-term strategy for COVID-19 control<sup>15,16</sup>. However, the utility of a long-term 76 serology-guided vaccination strategy for a pathogen with an imperfect correlate of protection is 77 78 unknown and will likely depend on unpredictable long-term dynamics of SARS-CoV-2 driven by waning immunity and new variant emergence<sup>17,18</sup>. Targeted vaccination strategies hold potential 79 in resource limited settings where vaccine provision is constrained<sup>19,20</sup>; however, there are few 80 mathematical models tailored to localized and distinct epidemic patterns in low income countries 81 despite their utility for optimizing vaccine strategies. 82 83 Our study uses a mathematical model of SARS-CoV-2 to determine the utility of incorporating

seroprevalence to trigger future COVID-19 re-vaccination efforts. We developed our model to
represent Mozambique, a resource-limited setting. Mozambique is notable for its early efforts in
measuring countrywide SARS-CoV-2 seroprevalence<sup>21</sup> and for studying seroprevalence in
children before commencing a resource-intensive campaign to vaccinate children<sup>22</sup>. We assess
the efficiency of a serology-guided re-vaccination strategy for COVID-19 in Mozambique under
uncertain epidemic dynamics over a 10-year time horizon.

## 90 **Results**

91 We modeled transmission dynamics and re-vaccination scenarios using a deterministic,

92 compartmental SEIR-like model<sup>23,24</sup> over a ten-year period starting in September 2022. The

model was stratified by age group (≤18 years, 19-49 and ≥50 years), urban/rural and 12

94 immunological tiers: combinations of four levels of vaccination status (unvaccinated to three

doses) and three levels of SARS-CoV-2 exposure status (unexposed to two prior exposures)

96 with lower susceptibility for increased exposure. For long-term SARS-CoV-2 dynamics, we

incorporated seasonality $^{25,26}$  assuming annual increases in transmission in the cool, dry season

- 98 (April to July) and uncertainty in transmission intensity (annual  $R_t$ ). We assessed a strategy of
- repeat boosting for older adults ( $\geq$ 50 years), likely the most cost-effective<sup>27–30</sup>, and compared
- 100 the impact of timing additional boosters guided by population-level seroprevalence estimates to
- 101 the impact of vaccinating at fixed time intervals. We integrated empirical data from Mozambique

on vaccine coverage, human contact patterns collected during the pandemic and survey-derivedseroprevalence.

- 104 Model calibration
- 105 Our historical model projection matched the COVID-19 epidemic waves observed in
- 106 Mozambique between 2020 and August 2022 (Fig 1) and our modeled seroprevalence closely
- 107 reflected historical estimates sampled at various times points in Mozambique across three age
- 108 groups in both urban and rural settings (Fig 1 & SI.7).
- 109 At the start of model projections (September 2022), the median seroprevalence was 56.5%,
- 110 86.0% and 84.3% for children, adults, older adults, respectively, based on model calibration. At
- this time, the estimated distribution of individuals who were fully susceptible (no exposure
- through infection or vaccination), partially susceptible and fully immune was 16.6%, 67.0%,
- 113 16.4% for children, 0.6%, 67.9%, 31.5% for adults and 1.3%, 68.3%, 30.6% for older adults.
- 114 Calibrated primary series vaccine coverage among adults and older adults was 93% and 96%,
- respectively, comparable to the data. For children who were ineligible for vaccination, immunity
- 116 was acquired from natural infection alone.
- 117



Figure 1. (Left) Modeled historical epidemic of cases per 100 persons using the top performing calibrated parameters (shaded grey=range of modeled cases per 100, dotted blue=reported

120 cases per 100 accounting for 1/90 underreporting for the first two waves, 1/100 underreporting

121 for the third wave, 1/120 underreporting for the fourth wave). Ranges reflect choice of calibration

# rather than uncertainty (Right) Modeled seroprevalence compared to seroprevalence estimated from serological studies during various periods of the pandemic in Mozambigue.

124

### 125 Description of simulated epidemic and changing immunity

126 Long-term COVID-19 epidemic patterns will likely be driven by immune waning and immune 127 escape<sup>17,31</sup>. We focused on modelling long-term dynamics driven by the former, assuming that a 128 re-vaccination strategy triggered by seroprevalence is more likely to be beneficial under an 129 epidemic driven by waning immunity. Under this assumption, the ten-year projection with no re-130 vaccination results in multiple peaks that are on average most intense in the second year and 131 diminish over time due to an increase in population-level immunity (Fig 2). The median 132 cumulative number of deaths across sampled  $R_t$  (mean = 5.5, SD = 0.2) over 10 years is 8605 (2.5th-97.5th percentile: 8026-9218) for all ages, 100 (93-108) for children, 2224 (2066-2387) 133 for adults and 6281 (5860-6722) for older adults (SI.5.1). Seroprevalence declines over time 134 135 and increases modestly following surges in cases. 136 137 We further observed from our model that 31% of older adults were fully immune before the start of the forward simulation, of which 58% had protection from vaccination alone with no prior 138 139 infection. The proportion immune reduces over the next year as individuals lose their full

- 140 protection and become increasingly susceptible to infection. This immunity gap drives a large
- 141 wave in 2025 which infects 30% of the population, resulting in a shift in susceptibility whereby
- individuals transition from vaccine-only protection to hybrid protection from both vaccination and
- infection (Fig 2). The shift leads to smaller subsequent waves, in line with evidence of increased
- 144 protection from hybrid immunity $^{32-35}$ .
- 145 Descriptive results from re-vaccination strategies

146 For all re-vaccination scenarios, we trigger a vaccination campaign where 50% of the older adult 147 population is vaccinated over a 30-day period. A strategy in which re-vaccination is triggered at a higher seroprevalence threshold (ex. 80%) increases the number of vaccination campaigns 148 149 and cumulative vaccine doses needed. While only three campaigns (or 1.9 million doses) are 150 needed to maintain a seroprevalence of at least 50% among older adults, 22 campaigns (or 151 13.9 million doses) would be needed to maintain a seroprevalence of at least 80% (SI.5.1). Using a 50% seroprevalence threshold, re-vaccination is first triggered after 4.5 years. Given 152 153 the higher intensity of earlier epidemic waves, the late re-vaccination trigger has little impact on

the epidemic trajectory and total disease burden. In comparison, using a 65% and 80%

- seroprevalence threshold triggers the first re-vaccinations after 2.3 years and 109 days,
- respectively. Using either of these thresholds to trigger re-vaccination reduces the size of early
- 157 waves compared to the 50% threshold, but is at the expense of more frequent vaccination
- campaigns. In the fixed annual and biennial re-vaccination strategies implemented without
- regard to seroprevalence, we simulated the first re-vaccinations at 300 days for a total of 10 and
- 160 5 campaigns over ten years, respectively, early enough to reduce the size of larger projected
- 161 epidemic waves in 2025.
- 162 Impact of different re-vaccination strategy on vaccine efficiency
- 163 Compared to a median of 6,281 total simulated deaths among older adults with no additional
- vaccinations over ten years, vaccinating older adults each time the seroprevalence among older
- adults falls below 50% and 80% results in a median of 5,017 (2.5<sup>th</sup>-97.5<sup>th</sup> percentile: 4,504-
- 166 5,507) and 1,835 (1,602-2,042) deaths, respectively (Fig.2 and SI.5.1), a reduction of 20
- and71%. The number needed to vaccinate to avert one death (NNT) reaches a minimum at a
- 168 50% threshold where 3 campaigns result in a median of 1,699 (1,445-1,875) fewer deaths and a
- 169 median NNT of 1,499 (1,252-1,905). The NNT increases with increasing seroprevalence
- threshold with a median NNT of 3,151 (2,943-3,429) for an 80% threshold. In comparison,
- annual and biennial re-vaccination of older adults results in a median of 2,999 (2,703-3,315) and
- 4,059 (3,646-4,579) deaths respectively and median NNTs of 1,941 (1,805-2,112) and 1,443
- 173 (1,223-1,733), respectively (Fig.2 and SI.5.1). In summary, vaccinating at seroprevalence
- thresholds of 50% 65% is more efficient than an annual strategy but less efficient than a
- 175 biennial strategy.



177

Figure 2. (Top row) Modeled 10-year seroprevalence (gray =  $2.5^{th}$ - $97.5^{th}$  percentile) over time 178 179 for children (lightest blue), adults (medium blue) and older adults >50 years (darkest blue) under 1) no additional vaccinations; 2) re-vaccinations timed by seroprevalence trigger thresholds of 180 50%, 65% and 80% and 3) re-vaccinations timed annually and biennially. (Middle row) Modeled 181 10-year cases per 100 individuals over re-vaccination scenarios (gray shading=ranges from 182 random Rt sampling, red= median); (Bottom row) Susceptibility among older adults. Colored 183 184 density represents population proportion within susceptible or immune tiers over time, ranging from fully immune (yellow) to up to 2 prior infections and 3 vaccination doses. The blue and 185 purple densities indicate proportion of individuals in the 2- and 3- vaccine dose susceptibility 186 tiers, respectively. The darkest shades within each color have no prior infection and are the 187 most susceptible, with lighter shades indicating more exposure and decreased susceptibility. 188 189 Individuals can wane from the 3-dose susceptibility tier to the 2-dose tier and from the 3-prior infection tier to the 2-prior infections at a rate of 1/365 days. The degree of susceptibility is 190 indicated in the grid legend and is relative to totally susceptible, with 1 indicating fully 191

susceptible and 0 fully immune. In scenarios with re-vaccination, campaigns generate spikes in
 the proportion of individuals fully immune (yellow). More frequent vaccination campaigns result

in higher proportion immune (yellow) and longer period in the compartment with highest

195 protection (purple). (Bottom left) Distribution of the number of vaccine doses needed to avert

one death (NNT) by re-vaccination timing strategy (biennial, annual, triggered based on

197 seroprevalence thresholds of between 50%-80%); (Bottom right) Cumulative deaths over ten

198 years among older adults. Error bar represents 2.5<sup>th</sup>-97.5<sup>th</sup> percentile of cumulative deaths for 199 older adults.

- 200 Tradeoffs in number-needed-to-treat
- 201 We explore two tradeoffs in the NNT of different re-vaccination strategies: tradeoffs in 1) NNT
- over time; 2) NNT and the number of deaths. The cumulative NNT is calculated by dividing the
- 203 cumulative number of vaccine doses by the cumulative number of deaths averted by the end of
- year. (Fig 3). The cumulative NNT is sensitive to the timing of the first vaccination, but
- 205 converges in later years. For example, using the 50% serological threshold delays vaccination
- 206 until year 4 resulting in a high NNT in year 4 compared to fixed-time strategies. However,
- 207 despite an early disadvantage in efficiency due to delayed vaccination, the 50% threshold
- 208 achieves parity with fixed-time strategies which first vaccinate in the year 1 for maximum impact.
- Across all re-vaccination strategies, the NNT rises over time suggesting that re-vaccination
- 210 strategies become less efficient as epidemic waves reduce.
- 211 We further observe a pattern of tradeoff where no single re-vaccination strategy can minimize
- both NNT and the cumulative deaths. Vaccinating at 80% seroprevalence minimizes the number
- of deaths but has a higher NNT compared to vaccinating at 50% seroprevalence and thus less
- efficient. Biennial re-vaccinations and re-vaccinating at 50% and 55% seroprevalence minimizes
- the NNT. Across these three strategies, the biennial strategy produces the lowest number of
- 216 deaths compared to the two serology-triggered strategies, largely owing to an earlier timing of
- 217 first vaccination campaign (Fig 3).



218

Figure 3. (Left) Tradeoffs over time in efficiency estimated by the cumulative number of vaccine
 doses needed to avert one death (NNT) for the high waning immunity epidemic scenario.

221 Cumulative NNT is calculated by summing the number of vaccine doses provide by the end of

each simulation year and dividing by the cumulative number of deaths averted by the end of

each year. (Right) Scatterplot of tradeoffs in efficiency (NNT) and number of deaths for the high
 waning immunity epidemic scenario.

225

226 Sensitivity analysis of waning antibody rates

The time-to-seroreversion of serological markers can vary by target and the choice of titer

thresholds used to determine seropostivity<sup>36</sup>. For example, estimates of time-to-seroreversion

after one infection exposure range from 250 days to 730 days for anti-N IgG and 255 days to

1500 days for anti-S  $IgG^{36-38}$ , with evidence suggesting more durable antibodies after repeated

exposures<sup>13,39,40</sup>. We vary the modeled rate of antibody waning to explore outcomes across a

range of antibody targets and seroprevalence trigger thresholds that could be used as part of a

surveillance program, assuming multiple exposures, from fastest (time to seroreversion of 500

days) to slowest (time to seroreversion of 3000 days). Under assumptions of relatively durable

hybrid immunity after multiple exposures, we find that choosing a serological marker with rapid

time-to-seroreversion relative to waning immunity results in early first vaccination and frequent

237 subsequent re-vaccination, a highly inefficient strategy. A marker with slower waning and higher

correlation with waning immunity is more likely to be efficient compared to annual and biennial

239 re-vaccination strategies.



240

248

Figure 4. (Left) Median NNT by seroprevalence threshold for re-vaccination over various rates
of time-to-seroreversion (lightest purple = slowest time-to-seroreversion, darkest purple =
fastest time-to-seroreversion), with annual (orange) and biennial (yellow) NNTs for reference.
Inset shows the modeled rates of different antibody waning compared to waning immunity
(Dirth) Contact plat of uppering efficiency (NNT) and time of first uppering to part of the product of

(pink). (Right) Scatter plot of vaccine efficiency (NNT) and time of first vaccination over random
 Rt simulation runs under different rates of time-to-seroreversion.

247 Sensitivity analysis on epidemic assumptions

249 While the expectation is that, SARS-CoV-2 will begin to display regular, seasonal epidemic

250 patterns, so far, SARS-CoV-2 waves have occurred at irregular times throughout the year<sup>41</sup>,

which may continue into the near future. We conducted sensitivity analysis to explore the

252 relative vaccine efficiency of serologically-triggered versus fixed-time re-vaccination strategies

under randomly-timed epidemics by randomizing the timing of annual increases in transmission

each year. We find that triggering re-vaccination at the 50% seroprevalence threshold is more

efficient than both annual and biennial re-vaccinations. Compared to seasonal epidemic

- 256 patterns, under randomly-timed epidemics lower trigger thresholds for serologically-guided
- scenarios displayed wide variations in efficiency and deaths averted. In some simulation runs,
- 258 serologically-triggered strategies can be highly efficient while in others, sustained transmission
- 259 over several years delayed the timing of first vaccination leading to almost no deaths averted
- 260 (SI.6).

261 In a separate sensitivity analysis, we simulate future waves driven by increasingly transmissible

immune escape variants. We find a higher number of deaths, fewer deaths averted by re-

263 vaccination and lower efficiency but similar patterns in efficiency across re-vaccination timing

strategies whereby serologically-triggered strategies are not substantially more efficient thaneither annual or biennial strategies (SI.7).

#### 266 **Discussion**

267 We use a transmission model to examine the potential for serological surveillance to guide the 268 timing of future rounds of COVID-19 re-vaccination in Mozambigue, a resource-limited setting. 269 The effectiveness of timing vaccination campaigns guided by population-level prevalence thresholds of a serological marker will depend on future SARS-CoV-2 epidemic patterns and the 270 271 degree to which the serological marker indicates population-level immune status. Across 272 scenarios of waning rates of serological marker and epidemic patterns we explored, only a 273 lower seroprevalence threshold for triggering re-vaccination (50-60%) is likely to outperform a 274 fixed-time re-vaccination strategy with respect to efficiency. However, routine population-based sampling that can yield accurate and timely seroprevalence estimates will be costly. Given 275 minimal gains in efficiency even in the best-case scenarios, we conclude that there is unlikely to 276 277 be a cost-effective way to monitor population-level protection and reactively vaccinate the most 278 vulnerable population groups before observing increases in clinical cases and hospitalizations. 279 Further, when weighing tradeoffs between efficiency and deaths, we find that the biennial 280 strategy is most likely to maximize efficiency while minimizing deaths. Taken together, the 281 results from our modeling work favor the use of simpler fixed-time re-vaccination interval 282 strategies over serological-triggered re-vaccination strategies. 283 284 Our results contradicted our belief that using serology-triggered re-vaccination strategies to 285 target time periods of greater susceptibility would substantially outperform fixed-time re-286 vaccination strategies. In our exploration of reasons for similar efficiencies between the two 287 strategies, we found that modeled seroprevalence did not necessarily predict deaths. We 288 expected a negative correlation between seroprevalence and deaths where higher seroprevalence leads to lower deaths. While this correlation was observed within each year, we 289 found an overall positive correlation over the 10-year period (SI.5.4). Large, early epidemic 290 waves that resulted in more deaths among older and younger populations alike were driven by 291 292 lower protection among children. These larger early waves occurred despite high 293 seroprevalence among older adults, making it a weaker marker for overall epidemic size.

295 Our modeling work provides a framework for explicit considerations necessary for population-296 level serological surveillance to guide response. The degree of correlation between 297 seroprevalence and immunity is likely to impact its utility. In the case of SARS-CoV-2, studies have explored the level of protection conferred by titers of different serological markers at the 298 299 individual-level<sup>42,43</sup>. To formulate a feasible population-based strategy using information on correlates of protection requires its translation into measurable population-level estimates. 300 301 Selecting an appropriate serological marker and a corresponding titer threshold that can reflect 302 complex population-level susceptibility to future outbreaks and can be monitored through 303 population surveillance will be key. Relatedly, considerations must be given to selecting the 304 most suitable seroprevalence trigger threshold. In the case of measles, where the goal of 305 vaccination is to eliminate infections, the proposed serologically-guided vaccination strategy uses the herd immunity thresholds as the trigger for vaccination campaigns<sup>14</sup>. In contrast, the 306 primary objective of SARS-CoV-2 vaccination is to reduce severe outcomes and deaths. 307 308 Without defined population-level thresholds predictive of severe outcome potential, our 309 modeling tested a range of seroprevalence thresholds as vaccination triggers. Our analysis 310 demonstrated, that in the context of durable hybrid immunity against severe outcomes, using a serological marker with slower waning to trigger re-vaccination is most likely to be efficient 311 312 against fixed-time strategies. These considerations are further applicable to other infectious 313 diseases that can benefit from leveraging serosurveillance to inform public health interventions44,45 314

315

Our analysis is the first study to assess the efficiency of serological triggers for a long-term 316 SARS-CoV-2 strategy. Our model structure extends previously published models<sup>26,27</sup> by 317 318 explicitly representing complex immunity profiles of hybrid immunity. Since the duration and extent of protection conferred by prior exposures depends on whether an individual's particular 319 history includes infection by the virus or one or more vaccine doses<sup>31</sup>, an explicit representation 320 321 more accurately reflects population-level susceptibility that dynamically changes in response to 322 vaccinations, infections and waning immunity. Unlike other models, we further decouple antibody waning from immunity waning with both processes informed by available data, which 323 324 more accurately reflects their varying timelines and dynamics. Our NNT values are comparable to two other modelling studies that evaluated the efficiency of booster doses in LMICs where 325 one estimated the NNT to be around 4000 for one booster for all eligible age groups<sup>29</sup> and a 326 327 second estimated the NNT to be 1453 for yearly boosters among those aged 60 years and 328 above<sup>30</sup>.

#### 329

330 We acknowledge several limitations. There is considerable uncertainty around model 331 parameters, especially for the extent of protection conferred by multiple exposures and duration of antibody waning<sup>46</sup>. Our parameterization reflected the observed protection conferred by prior 332 exposures between March and January 2021, where cross protection against repeat infections 333 was predominantly driven by c the wild-type strain and variants up to omicron<sup>47–49</sup>. Future 334 335 variants may have greater or less cross protection against future infections than we have 336 modeled here. We assumed a seasonally-forced long-term transmission pattern based on 337 evidence from other respiratory illnesses in Mozambigue and from other human coronaviruses<sup>17,29,50,51</sup>. Their remains considerable uncertainty regarding the long-term 338 dynamics of endemic SARS-CoV-2 infection and dynamics proposed by our model served as a 339 340 base case scenario that allowed for an evaluation of the merits of using a seroprevalence-341 guided long-term re-vaccination strategy. We tested other epidemic patterns as sensitivity

342 analysis and found comparable results.

In conclusion, our study demonstrates that regularly-timed re-vaccinations for older adults,
particularly prior to the SARS-CoV-2 season is likely to be more efficient and similarly effective
as a serological-triggered re-vaccination strategy. This finding was contrary to our expectation
that a serological-triggered strategy could prevent periods of enhanced population risk due to
waned protection.

#### 348 Methods

#### 349 *Model structure*

We extend a deterministic, compartmental SEIR-like model<sup>23,24</sup> to incorporate demographic 350 351 strata of age group ( $\leq$ 18 years, 19-49 and  $\geq$ 50 years) and urban/rural and twelve tiers of 352 immunity status: combinations of four tiers of vaccine status (unvaccinated, vaccinated with one dose, two doses and three doses) and three tiers of exposure status (unexposed, one prior 353 354 exposure and two prior exposures) (Fig 5). The multiple tiers of immunity allow differential susceptibility based on prior exposure from either infection or vaccination. To summarize the 355 356 model design: after exposure, individuals enter a latent, non-infectious period (E), after which 357 they progress to either infectious and asymptomatic (A) or infectious and symptomatic (I). A 358 proportion of symptomatic individuals progress to more severe disease and are hospitalized (H). 359 A subset of those who are hospitalized ultimately die from SARS-CoV-2 (entering the D class).

360 All individuals who are not hospitalized recover (entering the R class) and can either be 361 seropositive ( $R_p$ ) or seronegative ( $R_n$ ). Individuals can also be vaccinated and, if unexposed, 362 enter the seropositive  $V_p$  or seronegative  $V_n$  classes immediately post-vaccination, if previously exposed, enter the seropositive  $R_p$  or seronegative  $R_n$  classes corresponding to their prior 363 infection tier. The R and V classes are temporarily immune to infections; however, immunity 364 wanes over time and individuals return to a partially susceptible class (Sp.1 for seropositive and 365 one prior infection and  $S_{n,1}$  for seronegative and one prior infection). The force of infection (SI.1. 366 Eq.1) is modified by probability of infection of exposed age group  $(\beta_i)$ , vaccine effectiveness 367 against infection, differential by 1-3 doses ( $VEI_{\nu}$ ), reduced susceptibility from protection from 368 prior infection  $(IP_{e})$ , increased variant transmissibility (for Delta and Omicron waves), immune 369 escape (applied to immunity tiers with prior exposure through either infection of vaccination), 370 371 age and rural/urban-specific contact rate ( $\chi_{j,i,m,k}$ ) and infection density within each demographic strata. Infected individuals who are asymptomatic have reduced transmissibility ( $\alpha_i$ ). The model 372 diagram is described in Figure 1, equations can be found in SI.1 and details on model 373

parameters, values, ranges and sources can be found in SI.2.





Figure 5. Schematic of an S-E-I-R-like compartment for a single demographic stratum (out of six total: three age groups in each of urban and rural) with four tiers of immunity shown (two tiers of vaccination: unvaccinated and one dose of vaccine, with the superscript V1 the vaccine dose and two tiers of exposure: no prior exposure and one exposure, with the subscript representing

the number of exposures). Individuals who recover from infection are immune for a period. The majority seroconvert after infection  $(R_p)$  while others do not  $(R_n)$ . Immunity for both seropositive  $(R_p)$  and seronegative  $(R_n)$  can wane over time, returning individuals to  $S_p$  and  $S_n$ , respectively, allowing for subsequent infection. Individuals in classes outlined in green are eligible for vaccination and move to a higher vaccine tier upon vaccination (not all arrows drawn explicitly in the diagram) The majority of individuals seroconvert after vaccination. Vaccinated individuals are temporarily immune before their immunity wanes. Individuals in vaccinated and previously

exposed strata have a reduced probability of infection and disease.

- 389 Seroconversion and seroreversion
- 390 Our model distinguishes between antibody positivity and immunity with separate seropositive
- and seronegative compartments in the S (susceptible), R (recovered) and V (vaccinated)
- 392 disease states. Presence of neutralizing antibodies following exposure is associated with
- reduced risk of severe disease<sup>42,52–55</sup>. Nevertheless, protection against infection also depends
- 394 on cell-mediated immunity and circulating variants. For example, individuals who lack
- neutralizing antibodies but have robust cell-mediated immunity can still be protected, while
- others with antibodies may remain susceptible to new immune-escaping variants<sup>42,56,57</sup>. Explicit
- 397 separation of immunity and serological status represents their imperfect correlation.
- Upon exposure through either infection or vaccination, individuals can seroconvert and become
- 399 seropositive. We assumed that 90%<sup>52,53</sup> of infected individuals seroconvert after recovering and
- 400 85%<sup>13</sup> of vaccinated individuals seroconvert upon moving to the vaccinated class following first
- 401 dose. Further, we assume 70% of seronegative individuals who receive an additional vaccine
- 402 dose will seroconvert<sup>58</sup>.
- 403 Over time, antibodies can wane with seropositive individuals seroreverting to seronegative. Fully
- 404 immune and seropositive individuals ( $R_p$ ) will serorevert to fully immune and seronegative ( $R_p$ )
- while partially susceptible and seropositive individuals ( $S_p$ ) will serorevert to partially susceptible
- and seronegative (S<sub>n</sub>). Waning rates differ by number of exposures, regardless of whether the
- 407 exposure was from vaccination or infection (e.g. antibody waning among those infected once
- 408 and vaccinated once is the same as waning among those vaccinated twice). Seroreversion is
- 409 fastest following the first exposure (1/500 days)<sup>59–62</sup> and declines after multiple exposures
- 410 (range of 1/2500 days after second exposure), in line with recent evidence that antibody titers
- 411 are higher and more persistent after multiple exposures<sup>63,64</sup>. To more appropriately represent
- the dynamics of waning antibodies in the real world, the rate of seroreversion is modeled as a
- 413 gamma distribution with four sequential compartments for the tiers with the fastest waning
- 414 rates<sup>65</sup> (SI.1 for details).

#### 415 Tiered susceptibility

Following infection or vaccination, we assume that individuals are fully immune for an average

- of 150 days before moving to a partially susceptible class. Among unvaccinated individuals, one
- and two prior infections will confer 65%<sup>32</sup> and 75% protection against infection ( $IP_e$ ),
- 419 respectively.
- 420 Vaccinated individuals move to a higher vaccination class (V1  $\rightarrow$  V2  $\rightarrow$  V3) with reduced rates
- 421 of infection and probability of hospitalization if infected. We parameterize vaccine effectiveness
- 422 based on performance of Astra Zeneca, the main vaccine used in Mozambique (and many
- 423 LMICs) and assume that one dose of vaccine reduces rate of infection ( $VEI_v$ ) by 50%, two
- doses by 60% and three doses by 70%. Further, one, two, three doses of vaccine reduces the
- 425 probability of progression to severe disease ( $VEP_v$ ) by 40%, 67% and 70% respectively. Overall
- 426 vaccine effectiveness against hospitalization is 70%, 87% and 91%<sup>66</sup> for one, two, three doses
- 427 of vaccine, respectively. For individuals with hybrid immunity, protection from infection is
- determined by  $1-(1-IP_e)^*(1-VEI_v)$ . SI.13 and SI.14 summarizes key evidence on infection and
- 429 vaccination effectiveness against susceptibility and severe disease stratified by variants used to
- 430 inform our immunity parameters.

## 431 Data sources and calibration

432 Model calibration provided an estimation of the population distribution across compartments and

- the seroprevalence at the start of the simulation (Sept 1, 2022), nine months after the last
- sampled seroprevalence in Mozambique. We incorporated data on social contact sampled in an
- urban and a rural area in Mozambique during the COVID-19 pandemic between March 2021-
- 436 March 2022; multiple cross-sectional seroprevalence data available at several time points from
- 437 an urban and a rural area (SI.3.3) in Mozambique; vaccination data and time-series of reported
- 438 cases<sup>67</sup> adjusted for an underreporting factor to calibrate the model.
- 439 The following parameters were calibrated using an approximate Bayesian approach:  $\beta_c$ ,  $\beta_a$ ,  $\beta_e$ .
- 440 (probability of infection upon contact among children, adults and older adults), increased
- 441 transmissibility and immune escape for Delta and Omicron variants and waning rate of
- 442 antibodies (SI.2). We defined a range of plausible priors for each parameter informed by
- literature review and prior experience calibrating a comparable model. The initial ranges for
- calibration can be found in SI.7. We used Latin hypercube sampling<sup>68</sup> to randomly sample from
- the pre-defined parameter space for each run.  $R_0$  from the sampled  $\beta$ s was calculated by
- identifying the dominant eigenvalue of the next generation matrix that incorporates both age-

specific mixing patterns and the age-specific probabilities of transmission ( $\beta_c$ ,  $\beta_a$ ,  $\beta_e$ )<sup>69</sup>. We 447 448 further constrained  $\beta$ s to sampled trios that met the pre-specified R<sub>0</sub>. We compared the modeled age-specific seroprevalence estimates after each wave to available seroprevalence information 449 as the primary target statistic (17 unique estimates). We conducted the calibration iteratively. 450 Initially, 5000 iterations were sampled from the initial range of parameter spaces. We then 451 identified parameter draws that performed in the top 10% based on the sum of square errors 452 453 across all seroprevalence estimates and where each modeled data point was within 5 percentage points of estimates measured from field studies. We then restricted the ranges for 454 455 each parameter and conducted another round of LHS sampling based on the new, restricted 456 ranges. This process was repeated 4 times until, iteratively narrowing the calibration range each 457 time. We then ranked each set of parameters by the sum of square errors for seroprevalence 458 estimates and conducted forward simulation using the top 10% (n=500). We then chose the set 459 of parameters that produced the median cases and epidemic trajectory over the 10-years 460 simulation period as the primary parameter values for the forward simulations. Sensitivity 461 analysis for the range of acceptable calibrated parameters (top 10%) to assess the degree to 462 which uncertainty in the calibrated values would affect our forward simulation results. Our calibrated values for transmissibility of the delta and omicron variants are in line with the 463 published literature<sup>70,71</sup>. Ranges from calibration reflect choice in calibration rather than 464 uncertainty. 465

#### 466 Forward simulation epidemiological scenarios

We simulated the epidemic forward for ten years from September 1, 2022. Dynamics of long-467 468 term immunity were simulated by allowing waning from the highest vaccination and infection tier 469 in addition to the modeled waning described earlier. This included: 1) waning immunity for 470 individuals who recovered after their third infection  $(R_{p,3}, R_{n,3})$  to the two-infection susceptible tier  $(S_{n,2}, S_{n,2})$  after a period of immunity and 2) waning immunity for individuals from the three-471 vaccine-dose susceptibility tier  $(S_P^{V3}, S_n^{V3})$  to the two-vaccine-dose susceptibility tier  $(S_P^{V2}, S_n^{V3})$ 472 473  $S_n^{V2}$ ) after a period of full immunity. We assumed annual waves driven by increases in 474 transmission in the cool, dry season (April-July in Mozambigue), informed by observational studies of early SARS-CoV-2 dynamics that cooler and dryer weather were moderately 475 associated with increased SARS-CoV-2 transmissibility<sup>25,72,73</sup>. The relationship between  $R_0(t)$ 476

- and the specific humidity q(t) is determined by a prior model<sup>25</sup>:  $R_0(t) = \exp(\alpha * q(t) + q(t))$
- 478  $\log(R_{0max} R_{0min})) + R_{0min}$ .

479 To represent uncertainty in future transmission, we sample  $R_{0max}$  for each year from a log 480 normal distribution (mean  $R_0 = 5.5$ , standard deviation = 0.2).  $R_{0min}$  is fixed at 2.05, marginally 481 lower than the transmissibility of the original Wuhan strain. Given unpredictable long-term transmission dynamics, we consider one scenario where future waves are driven by high rates 482 483 of immune escape and a second scenario where future waves are driven by high rates of waning immunity. In the high immune escape scenario, in addition to sampling  $R_{0max}$  from the 484 distribution, we enforce a general trend of yearly increases using the following formula: 485  $R_{0max}^{h}(yr) = R_{0max}(yr) \times 1.075^{yr}$ , where  $R_{0max}^{h}(yr)$  is the yearly  $R_{0max}$  for the immune escape 486 487 scenario,  $R_{0max}(yr)$  is the randomly sampled  $R_0$  and yr is years since start of simulation. In the waning immunity scenario, we allow for additional waning immunity from the highest three-488 489 exposure tier to the two-exposure tier (90% protection to 75% protection in the three-vaccine 490 dose tier and 86% protection to 67% protection in the two-vaccine dose tier). For each scenario,

491 we conducted 500 different runs, each with 10 randomly sampled  $R_0$  for each year.

### 492 Vaccination triggers and analytical outputs

493 Based on literature suggesting increased impact and cost-effectiveness of routine vaccination 494 for older adults compared to routine vaccination of other age groups, we focus on a strategy of 495 booster vaccination for older adults and compare the impact of timing additional doses guided 496 by population-level seroprevalence estimates or based on fixed intervals. When triggered in the 497 model, additional vaccination was provided to the older adult population at 2% (or ~28,000 498 doses) of the older adult population per day over a 30-day campaign period for 50% coverage per campaign, with the same vaccination rate applied to seropositive and seronegative 499 500 subgroups. A 30-day campaign was deemed feasible and vaccinating ~28,000 deemed achievable compared to the 100,000 doses provided per day during peak campaign periods for 501 502 the primary COVID-19 series in Mozambique<sup>74</sup>. Specifically, the timing of vaccination was 503 guided by: 1) seroprevalence thresholds among older adults ranging from 50-80% where 504 vaccination will be triggered when the seroprevalence falls below the threshold; 2) fixed time intervals where vaccination will be triggered annually or biennially, with the first vaccine 505 506 campaign triggered a year after the start of simulation.

507 Our primary outcome is the number of vaccinations provided to older adults needed to avert one 508 death in the population (or number-needed-to-treat, NNT), using the number of deaths when no 509 additional vaccinations are provided as the base case. The NNT allows more equitable 510 comparison between scenarios where vaccination is constantly triggered versus scenarios 511 where vaccination is rarely triggered, shedding insight on the efficiency and potential cost-

- 512 effectiveness of different vaccination timing strategies. We further present the number of deaths
- and the number of deaths averted compared to a no vaccination scenario and the number and
- 514 timing of additional vaccination campaigns.

#### 516 References

- Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500.
   doi:10.15585/mmwr.mm7013e3
- Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. *N Engl J Med*. Published online September 8, 2021.
   doi:10.1056/NEJMoa2110362
- Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a
   systematic review and meta-analysis. *Infect Dis Poverty*. 2021;10(1):132. doi:10.1186/s40249-021 00915-3
- Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. *The Lancet Infectious Diseases*.
   2022;22(9):1293-1302. doi:10.1016/S1473-3099(22)00320-6
- 5. Telenti A, Arvin A, Corey L, et al. After the pandemic: perspectives on the future trajectory of COVID-19. *Nature*. 2021;596(7873):495-504. doi:10.1038/s41586-021-03792-w
- Koelle K, Martin MA, Antia R, Lopman B, Dean NE. The changing epidemiology of SARS-CoV-2.
  Published online 2022:7.

Surie D, Bonnell L, Adams K, et al. Effectiveness of Monovalent mRNA Vaccines Against COVID-19–
 Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5
 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States,
 December 26, 2021–August 31, 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(42):1327-1334.
 doi:10.15585/mmwr.mm7142a3

- CDC Statement on ACIP Booster Recommendations | CDC Online Newsroom | CDC. Published
   September 2021. Accessed June 22, 2023. https://www.cdc.gov/media/releases/2021/p0924 booster-recommendations-.html
- World Health Organization. Interim statement on booster doses for COVID-19 vaccination.
   Published October 2021. Accessed October 3, 2022. https://www.who.int/news/item/04-10-2021 interim-statement-on-booster-doses-for-covid-19-vaccination
- 546 10. SAGE updates COVID-19 vaccination guidance. Accessed April 4, 2023.
   547 https://www.who.int/news/item/28-03-2023-sage-updates-covid-19-vaccination-guidance
- 548 11. Stoddard M, Yuan L, Sarkar S, et al. *The Impact of Vaccination Frequency on COVID-19 Public Health* 549 *Outcomes: A Model-Based Analysis*. Infectious Diseases (except HIV/AIDS); 2023.
   550 doi:10.1101/2023.01.26.23285076
- Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second dose of
   BNT162b2 or ChAdOx1. *The Lancet*. 2021;398(10298):385-387. doi:10.1016/S0140-6736(21)01642-1

- 13. Ward H, Whitaker M, Flower B, et al. Population antibody responses following COVID-19 vaccination
   in 212,102 individuals. *Nat Commun*. 2022;13(1):907. doi:10.1038/s41467-022-28527-x
- 14. Lessler J, Metcalf CJE, Cutts FT, Grenfell BT. Impact on Epidemic Measles of Vaccination Campaigns
   Triggered by Disease Outbreaks or Serosurveys: A Modeling Study. von Seidlein L, ed. *PLoS Med*.
   2016;13(10):e1002144. doi:10.1371/journal.pmed.1002144
- Bryant JE, Azman AS, Ferrari MJ, et al. Serology for SARS-CoV-2: Apprehensions, opportunities, and
   the path forward. *Sci Immunol*. 2020;5(47):eabc6347. doi:10.1126/sciimmunol.abc6347
- 16. dos Santos Ferreira CE, Gómez-Dantés H, Junqueira Bellei NC, et al. The Role of Serology Testing in
  the Context of Immunization Policies for COVID-19 in Latin American Countries. *Viruses*.
  2021;13(12):2391. doi:10.3390/v13122391
- 17. Antia R, Halloran ME. Transition to endemicity: Understanding COVID-19. *Immunity*.
   2021;54(10):2172-2176. doi:10.1016/j.immuni.2021.09.019
- 18. Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to
   endemicity. *Science*. 2021;371(6530):741-745. doi:10.1126/science.abe6522
- 19. Massinga Loembé M, Nkengasong JN. COVID-19 vaccine access in Africa: Global distribution, vaccine
  platforms, and challenges ahead. *Immunity*. 2021;54(7):1353-1362.
  doi:10.1016/j.immuni.2021.06.017
- Ayenigbara IO, Adegboro JS, Ayenigbara GO, Rowland O, Olofintuyi OO. The challenges to a
   successful COVID-19 vaccination programme in Africa. *Germs*. Published online 2021:14.
- 572 21. Ministério da Saúde Moçambique. COVID-19: Inquérito Sero-epidemiológico de SARS-CoV-2.
   573 Published 2021. Accessed May 4, 2023. https://www.misau.gov.mz/index.php/covid-19-inquerito 574 sero-epidemiologicos
- Arnaldo P, Mabunda N, Young PW, et al. Prevalence of SARS-CoV-2 antibodies in the Mozambican
   population: a cross-sectional Serologic study in three cities, July-August 2020. *Clinical Infectious Diseases*. Published online June 24, 2022:ciac516. doi:10.1093/cid/ciac516
- 578 23. Gallagher ME, Sieben AJ, Nelson KN, et al. Indirect benefits are a crucial consideration when
  579 evaluating SARS-CoV-2 vaccine candidates. *Nat Med*. 2021;27(1):4-5. doi:10.1038/s41591-020580 01172-x
- 581 24. Kraay ANM, Gallagher ME, Ge Y, et al. *Modeling the Use of SARS-CoV-2 Vaccination to Safely Relax* 582 *Non-Pharmaceutical Interventions*. Epidemiology; 2021. doi:10.1101/2021.03.12.21253481
- 583 25. Baker RE, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. Susceptible supply limits the role of climate
   584 in the early SARS-CoV-2 pandemic. *Science*. 2020;369(6501):315-319. doi:10.1126/science.abc2535
- Saad-Roy CM, Morris SE, Metcalf CJE, et al. Epidemiological and evolutionary considerations of
   SARS-CoV-2 vaccine dosing regimes. *Science*. 2021;372(6540):363-370.
   doi:10.1126/ccience.abg8662
- 587 doi:10.1126/science.abg8663

588 27. Barnard RC, Davies NG, Centre for Mathematical Modelling of Infectious Diseases COVID-19 working
 589 group, et al. Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the
 590 Omicron era. *Nat Commun.* 2022;13(1):4879. doi:10.1038/s41467-022-32404-y

- 591 28. Li R, Liu H, Fairley CK, et al. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination
  592 in the United States. *International Journal of Infectious Diseases*. 2022;119:87-94.
  593 doi:10.1016/j.ijid.2022.03.029
- 29. Cohen LE, Spiro DJ, Viboud C. Projecting the SARS-CoV-2 transition from pandemicity to endemicity:
   Epidemiological and immunological considerations. Lakdawala S, ed. *PLoS Pathog*.
   2022;18(6):e1010591. doi:10.1371/journal.ppat.1010591
- 30. Hogan AB, Wu SL, Toor J, et al. Long Term Vaccination Strategies to Mitigate the Impact of SARS CoV-2 Transmission: A Modelling Study. Epidemiology; 2023. doi:10.1101/2023.02.09.23285743
- 31. Wagner CE, Saad-Roy CM, Grenfell BT. Modelling vaccination strategies for COVID-19. *Nat Rev Immunol*. 2022;22(3):139-141. doi:10.1038/s41577-022-00687-3
- 60132. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and602Previous Infection. N Engl J Med. 2022;386(13):1207-1220. doi:10.1056/NEJMoa2118691
- 33. Tan ST, Park HJ, Rodríguez-Barraquer I, et al. COVID-19 Vaccination and Estimated Public Health
  Impact in California. *JAMA Netw Open*. 2022;5(4):e228526.
  doi:10.1001/jamanetworkopen.2022.8526
- Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2 infection and
  hybrid immunity against the omicron variant and severe disease: a systematic review and metaregression. *The Lancet Infectious Diseases*. Published online January 2023:S1473309922008015.
  doi:10.1016/S1473-3099(22)00801-5
- 35. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and Vaccination on
   Symptomatic Omicron Infections. *N Engl J Med*. 2022;387(1):21-34. doi:10.1056/NEJMoa2203965
- 612 36. Peluso M, Takahashi S, Hakim J, et al. SARS-CoV-2 antibody magnitude and detectability are driven
  613 by disease severity, timing, and assay. *SCIENCE ADVANCES*. Published online 2021:13.
- 37. Wei J, Matthews PC, Stoesser N, et al. Anti-spike antibody response to natural SARS-CoV-2 infection
  in the general population. *Nat Commun*. 2021;12(1):6250. doi:10.1038/s41467-021-26479-2
- Second Second
- Wei J, Matthews PC, Stoesser N, et al. SARS-CoV-2 antibody trajectories after a single COVID-19
  vaccination with and without prior infection. *Nat Commun*. 2022;13(1):3748. doi:10.1038/s41467022-31495-x

40. Berry AA, Tjaden AH, Renteria J, et al. Persistence of antibody responses to COVID-19 vaccines
among participants in the COVID-19 Community Research Partnership. *Vaccine: X.* 2023;15:100371.
doi:10.1016/j.jvacx.2023.100371

- 41. Branswell H. Covid-19 hasn't fallen into a seasonal pattern yet. STAT News. Published August 23,
  2023. Accessed August 29, 2023. https://www.statnews.com/2023/08/23/covid-19-has-not-yetfallen-into-a-seasonal-pattern/
- 42. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune
  protection from symptomatic SARS-CoV-2 infection. *Nat Med.* 2021;27(7):1205-1211.
  doi:10.1038/s41591-021-01377-8
- 43. Zar HJ, MacGinty R, Workman L, et al. Natural and hybrid immunity following four COVID-19 waves:
  A prospective cohort study of mothers in South Africa. *eClinicalMedicine*. 2022;53:101655.
  doi:10.1016/j.eclinm.2022.101655
- 44. Wiens KE, Jauregui B, Arnold BF, et al. Building an integrated serosurveillance platform to inform
  public health interventions: Insights from an experts' meeting on serum biomarkers. Kamel MG, ed. *PLoS Negl Trop Dis*. 2022;16(10):e0010657. doi:10.1371/journal.pntd.0010657
- 45. Dean NE, Howard DH, Lopman BA. Serological Studies and the Value of Information. *Am J Public Health*. Published online March 9, 2023:e1-e3. doi:10.2105/AJPH.2023.307245
- 46. Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic
  review. Mantis NJ, ed. *PLoS ONE*. 2020;15(12):e0244126. doi:10.1371/journal.pone.0244126
- 47. Lacy J, Mensah A, Simmons R, et al. Protective effect of a first SARS-CoV-2 infection from
  reinfection: a matched retrospective cohort study using PCR testing data in England. *Epidemiol Infect*. 2022;150:e109. doi:10.1017/S0950268822000966
- 644 48. Carazo S, Skowronski DM, Brisson M, et al. Protection against omicron (B.1.1.529) BA.2 reinfection
  645 conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care
  646 workers with and without mRNA vaccination: a test-negative case-control study. *The Lancet*647 *Infectious Diseases*. 2023;23(1):45-55. doi:10.1016/S1473-3099(22)00578-3
- 49. Tan CY, Chiew CJ, Pang D, et al. Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a
  highly vaccinated Asian setting: a test-negative design study. *Clinical Microbiology and Infection*.
  Published online August 2022:S1198743X22004189. doi:10.1016/j.cmi.2022.08.002
- 50. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of
   SARS-CoV-2 through the postpandemic period. Published online 2020:10.
- 51. Veldhoen M, Simas JP. Endemic SARS-CoV-2 will maintain post-pandemic immunity. *Nat Rev Immunol.* 2021;21(3):131-132. doi:10.1038/s41577-020-00493-9
- Lou B, Li TD, Zheng SF, et al. Serology characteristics of SARS-CoV-2 infection after exposure and
   post-symptom onset. *Eur Respir J*. 2020;56(2):2000763. doi:10.1183/13993003.00763-2020

- 53. Oved K. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 nonresponding seronegative subpopulation. Published online 2020:10.
- 54. Van Elslande J, Oyaert M, Ailliet S, et al. Longitudinal follow-up of IgG anti-nucleocapsid antibodies
  in SARS-CoV-2 infected patients up to eight months after infection. *Journal of Clinical Virology*.
  2021;136:104765. doi:10.1016/j.jcv.2021.104765
- 55. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for
   COVID-19 vaccines. *Vaccine*. 2021;39(32):4423-4428. doi:10.1016/j.vaccine.2021.05.063
- 56. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in
   Health Care Workers. *N Engl J Med*. 2021;384(6):533-540. doi:10.1056/NEJMoa2034545
- 57. Turner JS, Kim W, Kalaidina E, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma
  cells in humans. *Nature*. 2021;595(7867):421-425. doi:10.1038/s41586-021-03647-4
- 58. Plumb ID, Fette LM, Tjaden AH, et al. Estimated COVID-19 vaccine effectiveness against
  seroconversion from SARS-CoV-2 Infection, March–October, 2021. *Vaccine*. 2023;41(15):2596-2604.
  doi:10.1016/j.vaccine.2023.03.006
- 59. He Z, Ren L, Yang J, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2
  antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. *The Lancet*.
  2021;397(10279):1075-1084. doi:10.1016/S0140-6736(21)00238-5
- 674 60. Swartz MD, DeSantis SM, Yaseen A, et al. Antibody duration after infection from SARS-CoV-2 in the
  675 Texas Coronavirus Antibody Response Survey. *The Journal of Infectious Diseases*. Published online
  676 May 6, 2022:jiac167. doi:10.1093/infdis/jiac167
- 677 61. Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults
  678 from the general population of the United Kingdom. *Nat Microbiol*. 2021;6(9):1140-1149.
  679 doi:10.1038/s41564-021-00947-3
- 680 62. Wang H, Yuan Y, Xiao M, et al. Dynamics of the SARS-CoV-2 antibody response up to 10 months 681 after infection. *Cell Mol Immunol*. 2021;18(7):1832-1834. doi:10.1038/s41423-021-00708-6
- 63. Ward H. Population antibody responses following COVID-19 vaccination in 212,102 individuals.
   *Nature Communications*. 2022;13(907):6.
- 64. Ali H, Alahmad B, Al-Shammari AA, et al. Previous COVID-19 Infection and Antibody Levels After
  Vaccination. *Front Public Health*. 2021;9:778243. doi:10.3389/fpubh.2021.778243
- 686 65. Wearing HJ, Rohani P, Keeling MJ. Appropriate Models for the Management of Infectious Diseases.
  687 Ellner SP, ed. *PLoS Med*. 2005;2(7):e174. doi:10.1371/journal.pmed.0020174
- 66. Higdon M, Wahl B, Jones C, et al. A systematic review of COVID-19 vaccine efficacy and
  effectiveness against SARS-CoV-2 infection and disease. *Open Forum Infectious Diseases*.
  2022;ofac138. doi:https://doi.org/10.1093/ofid/ofac138

- 67. Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19). *Our World in Data*.
  692 Published online 2020. https://ourworldindata.org/coronavirus
- 68. Stein M. Large Sample Properties of Simulations Using Latin Hypercube Sampling. *Technometrics*.
  1987;29(2):143-151. doi:10.2307/1269769
- 695 69. Diekmann O, Heesterbeek JAP, Roberts MG. The construction of next-generation matrices for 696 compartmental epidemic models. *J R Soc Interface*. 2010;7(47):873-885. doi:10.1098/rsif.2009.0386
- 697 70. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher
  698 compared to SARS coronavirus. *Journal of Travel Medicine*. 2020;27(2):taaa021.
  699 doi:10.1093/jtm/taaa021
- 700 71. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of
   701 SARS-CoV-2 variants of concern as at June 2021. *Eurosurveillance*. 2021;26(24). doi:10.2807/1560 702 7917.ES.2021.26.24.2100509
- 703 72. Ma Y, Pei S, Shaman J, Dubrow R, Chen K. Role of meteorological factors in the transmission of
   704 SARS-CoV-2 in the United States. *Nat Commun*. 2021;12(1):3602. doi:10.1038/s41467-021-23866-7
- 73. Sajadi MM, Habibzadeh P, Vintzileos A, Shokouhi S, Miralles-Wilhelm F, Amoroso A. Temperature,
  Humidity, and Latitude Analysis to Estimate Potential Spread and Seasonality of Coronavirus Disease
  2019 (COVID-19). *JAMA Netw Open*. 2020;3(6):e2011834.
  doi:10.1001/jamanetworkopen.2020.11834
- 709 74. Total COVID-19 vaccine doses administered per 100 people. Our World in Data. Accessed July 1,
   2022. https://ourworldindata.org/grapher/covid-vaccination-doses-per-capita